Anebulo Pharmaceuticals (ANEB)
(Delayed Data from NSDQ)
$2.30 USD
+0.09 (4.07%)
Updated May 17, 2024 02:21 PM ET
After-Market: $2.02 -0.28 (-12.17%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ANEB 2.30 +0.09(4.07%)
Will ANEB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ANEB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANEB
Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
ANEB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?
Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?
Other News for ANEB
Anebulo Pharmaceuticals GAAP EPS of -$0.06 beats by $0.06
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Anebulo Pharmaceuticals reports Q3 EPS (6c) vs. (11c) last year
ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024